Pharmacyclics® Triggers Another Significant Milestone Payment for Phase III ... Sacramento Bee SUNNYVALE, Calif., Oct. 15, 2012 -- /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the international, randomized Phase III clinical trial (CLL3001) of ibrutinib (PCI-32765) in combination with bendamustine and rituximab in ... Pharmacyclics gets $50M milestone payment from J&J J&J keeps cash flowing on blockbuster Pharmacyclics deal for ibrutinib |
